BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; 14(12): 1862-1876 [PMID: 38222788 DOI: 10.4239/wjd.v14.i12.1862]
URL: https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm
Number Citing Articles
1
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic controlWorld Journal of Diabetes 2024; 15(2): 137-141 doi: 10.4239/wjd.v15.i2.137